Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) PT at $18.33

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) have received an average rating of “Buy” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Nine research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $18.33.

INZY has been the topic of a number of recent research reports. Wells Fargo & Company cut their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Wedbush restated an “outperform” rating and set a $12.00 price objective on shares of Inozyme Pharma in a research report on Friday, January 10th. Raymond James initiated coverage on Inozyme Pharma in a research report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Inozyme Pharma in a report on Wednesday, November 6th. Finally, HC Wainwright increased their price objective on shares of Inozyme Pharma from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, January 10th.

Inozyme Pharma Trading Down 3.4 %

Inozyme Pharma stock opened at $1.40 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. Inozyme Pharma has a 1 year low of $1.24 and a 1 year high of $7.80. The firm’s 50-day moving average is $2.26 and its 200-day moving average is $3.88. The company has a market cap of $89.94 million, a P/E ratio of -0.90 and a beta of 1.29.

Institutional Trading of Inozyme Pharma

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Inozyme Pharma during the fourth quarter valued at approximately $38,000. Virtu Financial LLC bought a new position in Inozyme Pharma during the 3rd quarter valued at $64,000. Palumbo Wealth Management LLC boosted its stake in Inozyme Pharma by 52.3% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock valued at $64,000 after purchasing an additional 7,995 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Inozyme Pharma in the 3rd quarter worth $81,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Inozyme Pharma in the 2nd quarter worth $84,000. 88.30% of the stock is owned by institutional investors and hedge funds.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.